Učitavanje...
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
BACKGROUND: People with hemophilia A or B with inhibitors are at high risk of bleeding complications. Infusion of bypassing agents, such as recombinant activated FVII (rFVIIa) and plasma‐derived activated prothrombin complex concentrate, are suggested as alternative therapies to factor VIII (haemoph...
Spremljeno u:
| Izdano u: | Cochrane Database Syst Rev |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Ltd
2017
|
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6483761/ https://ncbi.nlm.nih.gov/pubmed/28944952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011441.pub2 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|